Bringing the Oncology Community Together
Giants of Cancer Care 2015
SGR Repeal Bill Headed for Senate Following House Approval
A bill to repeal the SGR formula garnered critical support with a vote by the House of Representatives.
Role of Chemotherapy in CLL Shifts as Novel Agents Transform Clinical Practice
In an interview with OncLive, William G. Wierda, MD, PhD, discusses the changing role of chemotherapy in the management of CLL and the integration of novel agents into clinical practice.
Costly New Drugs Could Lead to Generation of Have-Nots in CLL
Ibrutinib and idelalisib will increase individual out-of-pocket and societal costs of caring for patients with CLL.
Frontline Pembrolizumab Bests Ipilimumab in Phase III Melanoma Trial
A trial comparing frontline pembrolizumab with ipilimumab for the treatment of advanced melanoma has met its progression-free survival and overall survival endpoints
Anti-PD-1 Therapy Poised to Take the Next Step in Melanoma
OncLive interviewed Jason J. Luke, MD, who discussed the clinical implications of immunotherapies in melanoma, with optimal sequencing and combinations emerging as the most pressing questions that researchers are seeking to answer in ongoing clinical trials.
Hope Rises for Immunotherapy in Breast Cancer
Elizabeth A. Mittendorf, MD, PhD, differentiates the main types of immunotherapy, highlights some of the most interesting results in breast cancer trials, and discusses why different types of immunotherapy might be appropriate for different types of breast tumors at various stages of development.
Dizon Discusses Advantages of IP Chemotherapy for Ovarian Cancer
In an interview with OncLive, Don Dizon, MD, explains the advantages of IP therapy and why further research and education are necessary to bring it to the forefront of ovarian cancer treatment.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2015
Intellisphere, LLC. All Rights Reserved.